Inflammatory Markers and Cognitive Performance in Patients With Schizophrenia Treated With Lurasidone

被引：0
作者：
Miller, Brian [1 ]
Pikalov, Andrei [1 ]
Siu, Cynthia [1 ]
Tocco, Michael [1 ]
Tsai, Joyce [1 ]
Harvey, Philip [1 ]
Loebel, Antony [1 ]
机构：
[1] Sunov Pharmaceut Inc, Ft Lee, NJ USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2017年 / 42卷
关键词：
Inflammatory Markers; Cognitive Functioning; Lurasidone; Lipids; Schizophrenia; Functional Capacity; Antipsychotic Treatment;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W172
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [1] Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice
    Fagiolini, Andrea
    Olivola, Miriam
    Lavatelli, Lisa
    Bellomo, Antonello
    Lobaccaro, Caterina
    Falsetto, Nathalie
    Micillo, Marco
    Cuomo, Alessandro
    ANNALS OF GENERAL PSYCHIATRY, 2022, 21 (01)
  • [2] Treatment persistence in patients with schizophrenia treated with lurasidone in Italian clinical practice
    Andrea Fagiolini
    Miriam Olivola
    Lisa Lavatelli
    Antonello Bellomo
    Caterina Lobaccaro
    Nathalie Falsetto
    Marco Micillo
    Alessandro Cuomo
    Annals of General Psychiatry, 21
  • [3] The relationship between inflammatory markers, clinical characteristics, and cognitive performance in drug-naïve patients with schizophrenia
    Sun, Xiaoxiao
    Luo, Guoshuai
    Li, Xue
    Wang, Jiayue
    Qiu, Yuying
    Li, Meijuan
    Li, Jie
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2023, 274 (6) : 1365 - 1374
  • [4] Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia
    Miller, Brian J.
    Pikalov, Andrei
    Siu, Cynthia O.
    Tocco, Michael
    Tsai, Joyce
    Harvey, Philip D.
    Newcomer, John W.
    Loebel, Antony
    COMPREHENSIVE PSYCHIATRY, 2020, 102
  • [5] Update on the development of lurasidone as a treatment for patients with acute schizophrenia
    Yasui-Furukori, Norio
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2012, 6 : 107 - 115
  • [6] Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression
    Modugula, Harika
    Kumar, Anoop
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (02) : 109 - 114
  • [7] Is Metabolic Syndrome Related to Cognitive Performance in Patients With Schizophrenia? Results From a Double-Blind, Active-Controlled, Lurasidone Study
    Hagi, Katsuhiko
    Nosaka, Tadashi
    Pikalov, Andrei
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S300 - S301
  • [8] The Relationship of Cognitive Dysfunction with Inflammatory Markers and Carotid Intima Media Thickness in Schizophrenia
    Imre, Okan
    Caglayan, Cuneyt
    Mustu, Mehmet
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (09):
  • [9] Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics
    Musil, Richard
    Spellmann, Ilja
    PHARMACOGENOMICS, 2018, 19 (12) : 927 - 930
  • [10] Thermal Balance of the Brain and Markers of Inflammatory Response in Patients with Schizophrenia
    S. A. Zozulya
    O. A. Shevelev
    D. V. Tikhonov
    A. N. Simonov
    V. G. Kaleda
    T. P. Klyushnik
    M. V. Petrova
    E. M. Mengistu
    Bulletin of Experimental Biology and Medicine, 2022, 173 : 505 - 509
12345